

Statin Therapy for Patients With Cardiovascular Disease (SPC)

Description of Measure

The percentage of males aged 21 – 75 and females aged 40-75 who are identified as having clinical atherosclerotic cardiovascular disease (ASCVD), and who were dispensed at least one high-intensity or moderate-intensity statin medication during the measurement year (MY) and who remained on a high-intensity or moderate-intensity statin medication for at least 80% of the treatment period.¹

The treatment period starts with the date of the first fill of the statin medication thru 31 Dec. MY.

Eligible Population

Members are identified by either of these two methods.

Event: Any of the following during Prior Year	Setting
Myocardial Infarct (MI)	Inpatient discharge claim
CABG	Any setting
PCI	Any setting
Other revascularization	Any setting
IVD Diagnosis who had least one encounter both in prior year and measurement year	
ICD10	Setting
I20.0, I20.2 -.9, I24.0, I24.8-.9, I25.10, I25.110 - .119, I25.5 - .6, I25.00 - .799, I25.810 - .84, I25.89 - .9, I63.20 - .39, I63.50, I63.511 –I65.29, I66.01 - .9, I67.2, I70.1 - .799, I70.92, I75.011 - .89, T82.855A - .8565	Outpatient, Telehealth, Acute Inpatient

Documentation

This measure is based on claims only.

Exclusions

Exclusions	Timeframe								
<ul style="list-style-type: none"> ■ Have a diagnosis of pregnancy during the measurement year (MY) or previous year (PY) ■ Have in vitro fertilization (IVF) in the MY or PY ■ Have ESRD or dialysis during the MY or PY 	Any time during the MY								
<ul style="list-style-type: none"> ■ Pregnancy ■ In vitro fertilization ■ Clomiphene – 1 dispensing event 	Any time during the PY or MY								
<ul style="list-style-type: none"> ■ ESRD ■ Dialysis ■ Cirrhosis 	Any time during the PY or MY								
<ul style="list-style-type: none"> ■ Myalgia ■ Myositis ■ Myopathy ■ Rhabdomyolysis 	Any time during the MY								
<p>Members 66 years and older by /Dec. 31 MY with Advanced Illness and Frailty.</p> <p>Members must meet BOTH advanced illness and frailty criteria to be excluded.</p>	<ul style="list-style-type: none"> ■ Frailty diagnosis in MY on 2 different DOS during the MY ■ Advanced Illness: Either of the following during the MY or PY <ul style="list-style-type: none"> - Advanced illness on 2 different DOS - OR Dispensed a dementia medication <table border="1" data-bbox="863 1285 1489 1703"> <thead> <tr> <th data-bbox="867 1289 1127 1373">Dementia Med Description</th> <th data-bbox="1127 1289 1485 1373">Prescription</th> </tr> </thead> <tbody> <tr> <td data-bbox="867 1373 1127 1486">Cholinesterase inhibitors</td> <td data-bbox="1127 1373 1485 1486"> <ul style="list-style-type: none"> • Donepezil • Galantamine • Rivastigmine </td> </tr> <tr> <td data-bbox="867 1486 1127 1617">Misc. Central Nervous System Agents</td> <td data-bbox="1127 1486 1485 1617"> <ul style="list-style-type: none"> • Memantine </td> </tr> <tr> <td data-bbox="867 1617 1127 1698">Dementia Combinations</td> <td data-bbox="1127 1617 1485 1698"> <ul style="list-style-type: none"> • Donepezil-memantine </td> </tr> </tbody> </table>	Dementia Med Description	Prescription	Cholinesterase inhibitors	<ul style="list-style-type: none"> • Donepezil • Galantamine • Rivastigmine 	Misc. Central Nervous System Agents	<ul style="list-style-type: none"> • Memantine 	Dementia Combinations	<ul style="list-style-type: none"> • Donepezil-memantine
Dementia Med Description	Prescription								
Cholinesterase inhibitors	<ul style="list-style-type: none"> • Donepezil • Galantamine • Rivastigmine 								
Misc. Central Nervous System Agents	<ul style="list-style-type: none"> • Memantine 								
Dementia Combinations	<ul style="list-style-type: none"> • Donepezil-memantine 								

Condition	ICD-10-Code
Myalgia	M79.10 – M79.12; M79.18
Myositis	M60.80 – M60.819; M60.821 – M60.829; M60.831 – M60.839; M60.841 – M60.849; M60.851 – M60.859; M60.861- M60.869, M60.871 – M60.879; M60.88; M60.89
Myopathy	G72.0; G72.2; G72.9
Rhabdomyolysis	M62.82
Cirrhosis	K70.30; K70.31; K71.7; K74.3 – K74.5; K74.60; K74.69; P78.81
ESRD	N18.5; N18.6; Z99.2

Medications

High-intensity Statin Therapy	Moderate-intensity statin therapy	
<ul style="list-style-type: none"> ■ Atorvastatin 40 – 80mg ■ Amlodipine-atorvastatin 40 – 80mg ■ Rosuvastatin 20 - 40mg ■ Simvastatin 80mg ■ Ezetimibe- simvastatin 80mg 	<ul style="list-style-type: none"> ■ Atorvastatin 10 - 20mg ■ Amlodipine-atorvastatin 10 - 20mg ■ Rosuvastatin 5 - 10mg ■ Simvastatin 20 - 40mg ■ Ezetimibe-simvastatin 20 - 40mg 	<ul style="list-style-type: none"> ■ Pravastatin 40 - 80mg ■ Lovastatin 40mg ■ Fluvastatin 40 – 80mg ■ Pitavastatin 1 – 4mg
Tips for Success	<ul style="list-style-type: none"> ■ Education patients on the importance of statin medications in reducing cardiovascular risk, regardless of cholesterol levels. ■ Start low, go slow’ when starting patients on a statin to reduce potential for side effects and improve adherence. <ul style="list-style-type: none"> - Consider decreasing the frequency of long-acting statins, rosuvastatin and atorvastatin, to every other day if the patient is unable to tolerate daily statin due to side effects. - If it is desired to keep the patient on a statin, consider switching to pravastatin or fluvastatin as they are the least likely to cause muscle toxicity. ■ In patients with chronic liver disease, who require a statin because of high cardiovascular risk, low dose pravastatin and abstinence from alcohol is recommended. ■ Atorvastatin and fluvastatin are preferred in patients with severe renal impairment. 	

Resources

I. National Committee for Quality Assurance, HEDIS® Measurement Year 2024 Volume 2 Technical Specifications for Health Plans

Arkansas Blue Medicare is an affiliate of Arkansas Blue Cross and Blue Shield. Arkansas Blue Cross and Blue Shield is an Independent Licensee of the Blue Cross and Blue Shield Association. © 2023 Arkansas Blue Cross and Blue Shield. All rights reserved.